The adjuvant use of lansoprazole, clonazepam and dimenhydrinate for treating intractable hiccups in a patient with gastritis and reflux esophagitis complicated with myocardial infarction: a case report by Georgi Maximov & Deepak Kamnasaran
Maximov and Kamnasaran BMC Research Notes 2013, 6:327
http://www.biomedcentral.com/1756-0500/6/327CASE REPORT Open AccessThe adjuvant use of lansoprazole, clonazepam
and dimenhydrinate for treating intractable
hiccups in a patient with gastritis and reflux
esophagitis complicated with myocardial
infarction: a case report
Georgi Konstantinov Maximov1 and Deepak Kamnasaran2*Abstract
Background: Hiccup (Singultus) is a sudden and involuntary contraction of the diaphragm followed by a sharp
closure of the epiglottis which results in the production of a specific “hic” sound. Normally, hiccups are treated without
intervention. Intractable hiccups occur rarely but are a disturbing symptom underlying other health related disorders.
Case presentation: We report the clinical case of a 67-year-old male patient with myocardial infarction accompanied
by intractable hiccups during the course of 8 months, and who was non-responsive to chlorpromazine or
metoclopramide, and baclofen; drugs routinely used to treat this condition. This sustained hiccup had severely
restricted the patient's ability to intake food and sleep. To explore alternative treatments, we investigated the adjuvant
administration of lansoprazole, dimenhydrinate and clonazepam in this patient. We discovered that this drug
combination was capable of successfully terminating his intractable hiccups, with no further evidence of recurrence.
No similar treatment is previously reported for intractable hiccups. We further suggest a hypothesis concerning a
potential mechanism on the anti-hiccup effect of dimenhydrinate.
Conclusion: We identified that the adjuvant use of lansoprazole, clonazepam and dimenhydrinate was capable of
attenuating the symptoms of our patient with intractable hiccups.
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Hiccups, also known as ”singultus” or synchronous
diaphragmatic flutter means “to gasp” or “sigh” [1,2].
These are involuntary multiple spastic contractions of
the diaphragm and intercostal muscles, which are rapidly
accompanied by uncontrollable inhalation and a sudden
closure of the respiratory tract by the epiglottis, resulting
in the classic “hic” sound. Episodes of hiccups involve
the unilateral contraction of the left hemi-diaphragm in
approximately 80% of cases and with a frequency ranging
from 4 – 60 [2]. This phenomenon has little variability
among individuals [2], and sometimes both sides of the* Correspondence: deepak.kamnasaran@crchul.ulaval.ca
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Hiccups are usually benign and self – limited, usually
ceasing within minutes and do not require medical
treatment [4]. However, hiccups lasting more than
48 hours are categorized as “persistent”, while those
lasting more than one month are referred to as ”intractable”
[3,5]. Hiccups may persist for months or even years. In fact,
severe hiccups are responsible for approximately 4000
annual hospitalizations in the United States [2].
Hiccups may occur at any age including healthy neo-
nates who, in breast feeding, can simultaneously gulp a
considerable amount of air into the stomach, which then
presses against the diaphragm to produce hiccups. In
our lifetime, each of us has experienced hiccups at
some time or another. According to the phylogeneticoMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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lung respiration; and may potentially explain frequent
hiccups among premature infants with pulmonary hypopla-
sia. Generally, hiccups are harmless and the duration is
short. Sometimes these occur for no specific reason, while
in other cases, are triggered by a stomach filled with excess
food, carbonated beverages or aerophagia, leading to
exerting pressure on the diaphragm. Alternatively, the rapid
swallowing of food, large volumes of cold beverages with
hot meals, very hot or very spicy food, or even excessive
amounts of alcohol can induce hiccups. Hiccups can also
be triggered by continuous loud laughter, extended
inhalation of tobacco or cannabis smoke or even
stress among healthy individuals. However, persistent
or intractable hiccupps may be accompanied by various
serious medical conditions such as myocardial infarction
[4,6-11] (Table 1), and therefore warrant pharmacological
interventions. In this article, we report the treatment of a
patient with intractable hiccups, using lansoprazole,
dimenhydrinate and clonazepam, which was successful in
attenuating the symptoms with no further evidence of
recurrence.
Case presentation
The patient was male, 67 years of age, who complained
of having intractable hiccups for a period of 8 months
which had occurred on the fourth day after reanimation
related to acute myocardial infarction. Since then, he
had persistent hiccups which impaired his ability to eat
and sleep. During this period, he occasionally vomited
while the sleep deprivation contributed to having acute
weight loss. The patient was diagnosed with gastritis,
reflux esophagitis, mitral insufficiency and prostate aden-
oma. His neurological status showed no abnormalities. In
addition, none of his family members had similar symp-
toms. Treatment with routine medications including
those typically prescribed in intractable hiccup casesTable 1 Medical conditions accompanying persistent or intrac
Medical di
Cardiovascular disorders myocardial ischemia; angina pectoris; pericard
symptom [4]; internal jugular vein cannulation
Esophago-gastrointestinal
disorders
esophageal and gastric distention; erosive eso
duodenal ulcers; gastric, pancreatic and colon
gastric outlet obstruction; small bowel obstruc
Central nervous system
disorders
traumatic brain injury; brain abscess; meningit
infarction [2,3]; brain stem tumor (as primary m
Pulmonary and thoracic
disorders
pneumonia; pleuritis; asthma; lung tumors; tho
local nerve compression or infection; broncho
Renal disorders renal failure; uremia; renal cancer; hypernephr
Electrolyte and metabolic
disorders
hyponatremia; hypokaliemia; hypocalcaemia; a
Others local and general anesthesia; alcohol intake; pwas as follows: chlorpromazine, metoclopramide and
baclofen, and all unfortunately were ineffective in this
patient. Therefore, we investigated the adjuvant dose
of lansoprazole (15 mg daily), dimenhydrinate (25 mg,
trice daily) and clonazepam (0.5 mg, twice daily) on the
patient. With this treatment regimen, his intractable hic-
cups were completely attenuated on the third day with no
adverse side-effects documented. No further administration
of this drug regimen was necessary, and there was no
evidence of symptomatic recurrence.
Conclusion
Drug treatment is required when hiccups persist longer
than normal. However, it must be recognized that some
drugs could further aggravate the hiccups [2]. These include,
cisplatin, Cyclophosphamid®, carboplatin, docetaxel,
paclitaxel, etoposide, Gemcitabine-HCL®, irinotecan,
vindesine and Vinorelbin® [2], corticosteroids especially
dexamethasone [12], benzodiazepines especially Apo-
Diazepam® [2], anabolic steroids [2], opioids particularly
morphine [13], heroin methadone, antibiotics especially
ceftriaxone [14] and azithromycin [15]. The principal
treatment for chronic hiccups is currently with chlorpro-
mazine [16] and metoclopramide. In the United States,
chlorpromazine is the only Food and Drug Administration
approved drug to treat this symptom [3]. However, other
drugs may include the gamma aminobutyric acid agonist
baclofen [17] but unfortunately this is intolerable among
many elderly patients secondary to adverse side effects
[2]. Alternatively, another gamma aminobutyric acid
agonist, namely Gabapentin-GR®, a recent anti-epileptic
drug, shows improved efficacy and with less side effects
when treating intractable hiccups [18,19]. In contrast, the
classical anti-epileptic drugs Apo-Carbamazepine®, valproic
acid and phenytoin are rarely used because of their
adverse drug interactions. Moreover, the dopamine antag-
onist Apo-Haloperidol®, and the tricyclic anti-depressanttable hiccups
sorders
itis [2,3]; myocardial infarction (MI) [2,3,6]; MI as single presenting
(as a complication) [7]
phagitis; herpetic esophagitis; gastro-esophageal reflux; gastric and
cancers; hepatoma and liver metastasis; pancreatitis; cholecystitis; ascites;
tion; subdiaphragmatic abscess; gastrointestinal investigations [2,3]
is; brain stem lesion; medulla oblongata lesion; lateral medullary
anifestation) [8]; multiple sclerosis (as single symptom) [9]
racic herpes zoster; acute negative intrathoracic pressure; mediastinal
scopy [3,4]
oma [3,4]
zotemia; uncontrolled diabetes mellitus [3,4]
sychogenic origin disorders [3,4]
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with significant adverse side effects [2]. Other studies
suggest the use of calcium channel blockers nifedipine
[20], nimodipine [21] and lidocaine [22], non-opioid
analgesic nefopam [23], Amantidine® [24], olanzapine
[1], carvedilol [25], Methylphenidate-HCL® [26], all of
which may treat chronic hiccups, but warrant further
investigation. Interestingly, dexamethasone and midazolam,
although recognized to trigger the onset of hiccups, were
successfully utilized only in a few cases [2,27,28]. Marijuana,
although recognized as an opioid, was previously described
to potentially treat intractable hiccups [3,29], but is
subject to current controversy. Hence, it is imperative
to continue further investigations for the treatment of
intractable hiccups.
In our study, the rationale to use lansoprazole was to
suppress the patient's symptoms of gastritis and reflux
esophagitis. Principally, lansoprazole promotes the healing
of gastric and duodenal ulcers and treats gastrointestinal
reflux. Lansoprazole, a potent suppressor of gastric acid
secretion, is an inhibitor of the gastric H+, K+ - ATPase
(proton pump), which exchanges hydrogen and potassium
ions across the parietal cell membrane [30]. The crucial
structures for the central nervous system stimulation of
gastric acid secretion are the dorsal motor nucleus of the
vagal nerve, the hypothalamus and the solitary tract
nucleus [30], that predominantly modulate the activity of
the enteric nervous system via acetylcholine release from
the vagal efferent fibers. Lansoprazole diminishes the daily
production of acid (basal and stimulated) by 80% to 95%.
In fact, maximal suppression of acid secretion requires
several doses of the proton pump inhibitor. For example,
it may take 2 to 5 days of therapy with one daily dosage to
achieve 70% inhibition of proton pump activity that is
seen at a steady state [30]. Furthermore, lansoprazole, like
other proton pump inhibitors, is endowed with causing
only very few adverse effects.
Patients with intractable hiccups have impaired quality
of life leading to episodes of anxiety, depression, sleep
deprivation, vomiting, malnutrition, dehydration, weight
loss and speech problems [2]; hence requiring the need
for anti-anxiety therapy. Currently, benzopdiazepines
(especially clonazepam) and selective serotonine re-uptake
inhibitors, are most commonly used for treating anxiety
disorders. Benzodiazepines are speculated by some gastro-
enterologists to ameliorate a variety of “anxiety related”
gastrointestinal disorders. However, there is a paucity of
evidence for direct action. Clonazepam, like other
benzodiazepines, exert most of its effects by interacting
with the inhibitory neurotransmitter receptors which are
directly activated by gamma aminobutyric acid. As
the dose of a benzodiazepine is increased, sedation
progresses to hypnosis. The half-life of clonazepam in
plasma is about 1 day. In our patient, clonazepamwas administered in small doses due to its potent
myo-relaxant, tranquilizing, anxiolytic properties, and
notably, sleep-inducing effects. This ultimately resulted in
a minor sedation of the patient, while being adjuvantly
treated with dimenhydrinate.
Dimenhydrinate represents a combination of diphen-
hydramine and 8-chloro theophylline in equal molecular
proportions. We administered dimenhydrinate to our
patient, due to its property of being a first generation
histamine H1 receptors antagonist. H1 receptors are
distributed in smooth muscles, endothelial cells and
the central nervous system. H1 antagonists, such as
dimenhydrinate, inhibit the effect of histamine on
these structures. Likewise, it inhibits responses to
acetylcholine that is mediated by muscarinic receptors. H1
antagonists do not suppress gastric secretion but are most
useful when having sedative properties to treat acute types
of allergy and motion sickness. Dimenhydrinate has dual
functions of stimulating and depressing the central
nervous system. Central excitation is a striking feature
of overdose, while central depression on the other hand
usually results in diminished alertness and somnolence.
Following oral administration, the peak plasma concentra-
tions are achieved within 2 to 3 hours and the effect
usually lasting 4 to 6 hours. In our case, the dose of
25 mg, was in compliance with the age of the patient.
Our hypothesis, to explain the anti-hiccup effect of
dimenhydrinate is based on its property of being a
histamine H1 receptors antagonist. Myocardial infarction
results in myocardial tissue injury where basic polypeptides
like histamine are released. This can cause spasmogenic by
the binding of histamine to H1 receptors of the enteric
smooth muscles, thereby irritating the afferent branches
of the hiccup-reflex arch and subsequently the onset
of hiccups. Hence, treatments with dimenhydrinate
attenuate this process and can relieve the symptoms
of chronic hiccups.
In conclusion, we identified that the adjuvant use of
lanzoprazole, clonazepam and dimenhydrinate was cap-
able of terminating the symptoms of intractable hiccups
in our patient; findings which will require further inves-
tigations among other similar cases, in an effort to dis-
cover more effective or improved treatment regimens
for intractable hiccups.Consent
Written informed consent was obtained from the patient
for publication of this Case Report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.Competing interests
The authors declare no conflict of interest.
Maximov and Kamnasaran BMC Research Notes 2013, 6:327 Page 4 of 4
http://www.biomedcentral.com/1756-0500/6/327Authors’ contributions
GKM: co-wrote manuscript, conceptualized presentation of study design/data
analyses, clinically managed patient. DK: wrote manuscript, conceptualized
presentation of study design/data analyses. Both authors read and approved
the final manuscript.Acknowledgment
We thank Dr. Kam Kamnasaran for helpful comments on this manuscript.
Author details
1Medical Faculty, Medical University, Sofia, Bulgaria. 2Department of
Pediatrics, Laval University, Québec, QC, Canada.
Received: 8 June 2013 Accepted: 15 August 2013
Published: 16 August 2013References
1. Alderfer BS, Arciniegas DB: Treatment of intractable hiccups with
olanzepine following recent severe traumatic brain injury.
J Neuropsychiatry Clin Neurosci 2006, 18:551–552.
2. Marinella MA: Diagnosis and management of hiccups in the patient with
advanced cancer. J support Oncol 2009, 7:122–127.
3. Bredenoord AJ: Perspectives in clinical gastroenterology and hepatology.
Clin Gastroenterol Hepatol 2013, 11:6–12.
4. Davenport J, Duong M, Lanoix R: Hiccup as the only symptom of non-ST
-segment elevation myocardial infarction. Am J Emerg Med 2012,
30:266–270.
5. Howard RS: Persistent hiccups. BMJ 1992, 305:1237–1238.
6. Ikram H, Orchard RT, Read SE: Intractable hiccupping in acute myocardial
infarction. Br Med J 1971, 2:504.
7. Topaz O, Sharon M, Rechavia E, Mager A, Chetboun I: Traumatic internal
jugular vein cannulation. Ann Emerg Med 1987, 16:1392–1395.
8. Stotka VL, Barcay SJ, Bell HS, Clare FB: Intractable hiccough as the primary
manifestation of brain stem tumor. Am J Med 1962, 32:312–315.
9. Na SJ, Lee S, Chung TS, Choi YC, Lee KY: Pneumomediastinum due to
intractable hiccups as the presenting symptom of multiple sclerosis.
Yonsei Med J 2005, 46:292–295.
10. McAllister RK, McDavid AJ, Meyer TA, Bittenbinder TM: Recurrent persistent
hiccups after epidural steroid injection and analgesia with bupivacaine.
Anesth Analg 2005, 100:1834–1836.
11. Todisko T, Todisco C, Bruni L, Donato R: Chin stimulation: a trigger point
for provoking acute hiccups. Respiration 2004, 71:104–108.
12. Ross J, Eledrisi M, Casner P: Persistant hiccups induced by
dexamethasone. West J Med 1999, 170:51–52.
13. Wilcox SK: Persistent hiccups after slow-release morphine. Palliat Med
2005, 19:568–569.
14. Bonioli E, Bellini C, Toma P: Pseudolithiasis and intractable hiccups in a
boy receiving ceftriaxone. N Engl J Med 1994, 33:1532–1533.
15. Jover F, Cuadrado JM, Merino J: Possible azithromycin-associated hiccups.
J Clin Pharm Ther 2005, 30:413–416.
16. Friedgood CE, Ripstein CB: Chlorpromazine (Thorazine) in the treatment
of intractable hiccups. JAMA 1955, 157:309–310.
17. Turkuilmaz A, Eroglu A: Use of baclofen in the treatment of esophageal
stent-related hiccups. Ann Thorac Surg 2008, 85:328–330.
18. Porzio G, Aielli F, Narducci F, Varrassi G, Ricevuto E, Ficorella C, Marchetti P:
Hiccup in patients with advanced cancer successfully treated with
gabapentin: report of three cases. N Z Med J 2003, 116:U 605.
19. Alonso–Navaro H, Rubio L, Jiminez–Jiminez FJ: Refractory hiccup:
successful treatment with Gabapentin. Clin Neuropharmacol 2007,
30:186–187.
20. Lipps DC, Jabbary B, Mitchell MH, Daigh JD Jr: Nifedipine for intractable
hiccups. Neurology 1990, 40:531–532.
21. Hernandez JL, Fernandez–Miera MF, Sampedro I, Sanroma P: Nimodipine
treatment for intractable hiccups. Am J Med 1999, 106:600–603.
22. Cohen SP, Lubin E, Stojanovic M: Intravenous lidocaine in the treatment
of hiccup. South Med J 2001, 94:1124–1125.
23. Bilotta F, Pietropauli P, Rosa G: Nefopam for refractory postoperative
hiccups. Anesth Analg 2001, 93:1358–1360.
24. Askenasy JJ, Bolagin M, Davidovitch S: Persistent hiccup cured by
amantadine. N Engl J Med 1988, 318:711–712.25. Stueber D, Swartz CM: Carvedilol suppresses intractable hiccups. J Am
Board Fam Med 2006, 19:418–421.
26. Marechal R, Berghmans T, Sculier P: Successful treatment of intractable
hiccup with methylphenidate in a lung cancer patient. Support Care
Cancer 2003, 11:126–128.
27. McKeogh M: Dexanetazone for intractable hiccoughs in a patient with
AIDS and PML. Palliat Med 1994, 8:337–338.
28. Wilcock A, Twycross R: Midazolam for intractable hiccup. J Pain Symptom
Manage 1996, 12:59–61.
29. Gilson I, Busalacchi M: Marijuana for intractable hiccups. Lancet 1998,
351:267.
30. Hoogerwerf WA, Pasricha PJ: Pharmacotherapy of gastric acidity, peptic
ulcers and gastroesophageal reflux disease. In Goodman and Gilman’s
“The Pharmacological basis of therapeutics”, Volume Chapter 36. 11th edition.
Edited by Brunton LL, Lazo JS, Parker KL. New York: McGraw – Hill Comp.
Inc; 2006:967–981.
doi:10.1186/1756-0500-6-327
Cite this article as: Maximov and Kamnasaran: The adjuvant use of
lansoprazole, clonazepam and dimenhydrinate for treating intractable
hiccups in a patient with gastritis and reflux esophagitis complicated
with myocardial infarction: a case report. BMC Research Notes 2013 6:327.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
